Shots:

• The two P-III PSOARING 1 and PSOARING 2 trials involve evaluating Tapinarof (1% dosed- qd) vs vehicle (qd) in 1-025 patients aged 18-75yrs. with plaque psoriasis
• Results: 2EPs & PRO- @12wks.- PASI90 (18.8% and 20.9%) vs (1.6% and 2.5%)- ≥4-point NRS improvement (67.5% and 59.7%) vs (46.1 and 31.3%)- improvement in QoL as measured by the DLQI- ≥90% reduction in one in five patients in PASI90- improvements in itch measured with PP-NRS
• Tapinarof is a steroid-free- cosmetically elegant- TAMA topical cream for the treatment of PsO and AD. The data will be included in NDA submission- expected in mid-2021

  Ref: Business Wire | Image: Business Wire